Published in
Elsevier, Value in Health, 10(20), p. 1260-1269
DOI: 10.1016/j.jval.2017.05.013
Links
Tools
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines
Journal article published in 2017 by
Isaac Corro Ramos 
,
Matthijs M. Versteegh ,
Rudolf A. de Boer,
Jolanda M. A. Koenders,
Gerard C. M. Linssen,
Joan G. Meeder,
Maureen P. M. H. Rutten-Van Mölken
,
Matthijs M. Versteegh ,
Rudolf A. de Boer,
Jolanda M. A. Koenders,
Gerard C. M. Linssen,
Joan G. Meeder,
Maureen P. M. H. Rutten-Van Mölken
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 